神经内分泌肿瘤治疗市场：依药物类别、按适应症、按配销通路、按地区

Neuroendocrine Tumor Treatment Market, By Drug Class, By Indication, By Distribution Channel, and By Region

出版日期: 2023年10月23日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年，全球神经内分泌肿瘤治疗市场规模将达32.4亿美元，预测期内（2023-2030年）年复合成长率为6.2%。

报告范围		报告详情
基准年	2022年	2023年市场规模	32.4亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	6.20%	2030年市场规模预测	49.4亿美元

图 1. 2023 年神经内分泌肿瘤治疗的全球市场占有率(%)（依药物类别）

神经内分泌肿瘤 (NET) 是一种始于人类神经内分泌系统特化细胞的癌症。这些细胞具有产生荷尔蒙的内分泌细胞和神经细胞的特征。神经内分泌系统的细胞存在于全身器官中并控制许多身体功能。神经内分泌肿瘤相对罕见，可发生在身体的任何部位，但最常见于肺部、阑尾、小肠、直肠和胰臟。神经内分泌肿瘤 (NET) 可以是无功能性（无症状）或功能性（有症状）的。功能性 NET 的症状因产生的荷尔蒙而异，但非功能性 NET 经常在因其他原因进行的影像检查中被发现。有些神经内分泌肿瘤具有侵袭性且生长迅速，而有些则生长缓慢。全球神经内分泌肿瘤治疗市场预计在未来年度将显着成长。这种增长是由多种因素推动的，包括神经内分泌肿瘤盛行率的增加、诊断技术的进步以及新的有效治疗方法的发展。神经内分泌肿瘤的治疗通常涉及手术、放射线治疗和药物治疗的组合。要进行的特定治疗类型通常取决于肿瘤的型态和阶段以及患者的一般状况。近年来，针对 NET 的标靶治疗的开发显着增加。这些治疗方法特异性针对癌细胞并最大限度地减少对健康细胞的损害。

市场动态

NET，有时称为类癌，可以有症状，也可以无症状，如果没有外在体征或症状，可能多年都未被发现。 NET 的一般特征是能够产生引起此症候群的胜肽。因此，增加治疗神经内分泌肿瘤患者的研发活动预计将在预测期内推动市场成长。例如，2022 年 3 月，商业阶段製药公司Amyrt Pharma plc 启动了Mycapssa（奥曲肽胶囊）的生物利用度研究，该研究计划在治疗与神经内分泌肿瘤(NET) 相关的类癌症状的3 期试验中取得成功。此外，根据与上述相同的资讯来源，根据这项研究，高达 80 mg 的 Mycapssa 剂量显示出预期的剂量比例和生物利用度，以及可接受的安全性和耐受性。

研究的主要特点

本报告对全球神经内分泌肿瘤治疗市场进行了详细分析，并提出了以2022年为基础的预测期（2023-2030）的市场规模和復合年度（年复合成长率）。
它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球神经内分泌肿瘤治疗市场的主要参与者进行了分析。
本研究涵盖的主要企业包括辉瑞公司、诺华公司、Ispen、Advanced Accelerator Inductions、Tarveda Therapeutics、Progenics Pharmaceuticals, Inc.、Hutchison Medipharma Limited、Dauntless Pharmaceuticals Inc.、Exelixis, Inc.。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场经营团队和行销策略做出明智的资讯。
全球神经内分泌肿瘤治疗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球神经内分泌肿瘤治疗市场的各种策略矩阵，将促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 3.24 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.20%	2030 Value Projection:	US$ 4.94 Bn

Neuroendocrine tumors (NETs) are a type of cancer that begins in the specialized cells of the body's neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body's organs and help control many of the body's functions. NETs are relatively rare and can occur anywhere in the body, but most commonly occur in the lungs, appendix, small intestine, rectum, and pancreas. Neuroendocrine tumors (NETs) can be non-functioning (without symptoms) or functional (with symptoms). Symptoms of functional NETs depend on which hormone is produced, while non-functioning NETs are often detected during imaging tests performed for other reasons. Some NETs are aggressive and fast-growing, while others are slow-growing. The global neuroendocrine tumor treatment market is expected to grow significantly in the coming years. This growth is driven by several factors, including an increase in the prevalence of neuroendocrine tumors, advancements in diagnostic technologies, and the development of new and effective therapies. The treatment of NETs typically involves a combination of surgery, radiation therapy, and medications. The specific type of treatment used is frequently determined by the tumor's form and stage as well as the patient's general condition. In recent years, there has been a significant increase in the development of targeted therapies for NETs. These therapies work by specifically targeting cancer cells, which can help minimize damage to healthy cells.

Market Dynamics

NETs are sometimes called carcinoid tumors, can be symptomatic or asymptomatic and may go undiscovered for years if there are no outward indications or symptoms. NETs are generally characterized by their ability to produce peptides that lead to their syndromes. Thus, increasing research and development activities for the treatment of patients suffering from neuroendocrine tumors is expected to foster market growth over the forecast period. For instance, in March 2022, Amyrt Pharma plc, a commercial stage pharmaceutical company, reported successful bioavailability study for Mycapssa (octreotide capsules) in a planned Phase 3 study in the treatment of carcinoid symptoms associated with neuroendocrine tumor (NET). Furthermore, from the same source above, according to the study, Mycapssa dosages up to 80mg showed the anticipated dose proportionality and bioavailability along with an acceptable safety and tolerability profile.

Key features of the study:

This report provides an in-depth analysis of the global neuroendocrine tumor treatment market and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuroendocrine tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Indications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine tumor treatment market

Detailed Segmentation:

By Drug Class:
- Somatostatin Analogs
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
By Indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others
By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Pfizer Inc
- Novartis AG
- Ispen
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Trends
Recent Launches and Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Neuroendocrine Tumor Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Neuroendocrine Tumor Treatment Market, By Drug Class, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Neuroendocrine Tumor Treatment Market, By Indication, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Gastrointestinal NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Lung NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Pancreatic NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Neuroendocrine Tumor Treatment Market, By Distribution Channel, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

8. Global Neuroendocrine Tumor Treatment Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa